Skip to navigation Skip to main content
  • Home
  • About us
  • Vision & Mission
  • Research Focus
    • spinal cord injury
    • neuroregeneration
    • novel molecules
    • peptide therapies
  • Projects
  • Insights
    • Articles
  • News & Updates
  • Contact us
Search
Menu

neuroregeneration

06 Jul

Polylaminin: A Biomimetic ECM Scaffold for Neural Repair

Introduction The adult central nervous system (CNS) has a limited capacity for self-repair. Followi...
Continue reading
16 May

Chondroitinase ABC (ChABC): Enzymatic Degradation of Inhibitory ECM After Spinal Cord Injury

Introduction After spinal cord injury (SCI), the central nervous system responds with inflammatio...
Continue reading
16 May

Axonis Therapeutics: Advancing KCC2 Modulation for Neural Recovery

Introduction Axonis Therapeutics is a biotechnology company developing first-in-class oral small-...
Continue reading
25 Feb

New Approaches to Modulating CSPG Signaling After Spinal Cord Injury

A recent wave of studies is taking a closer look at how chondroitin sulfate proteoglycans (CSPGs) co...
Continue reading
23 Feb

NVG-291: Exploring Its Potential in Spinal Cord Injury and Neuroprotection

Introduction NVG-291 is a promising experimental agent designed to address neuroinflammation, a key...
Continue reading
  • No.6&7, 10th floor, Mellat Tower, Vali-e-Asr St, Tehran, Iran
  • +98 21 2623 0998
  • +98 912 388 3863
  • info@neuraldaroo.com
  • behrad.khalaf@gmail.com

Quick Links:

  • Research Focus
  • About Us
  • News & Updates
  • Contact Us

Location

© Neural Drug Research
  • Home
  • About us
  • Vision & Mission
  • Research Focus
    • spinal cord injury
    • neuroregeneration
    • novel molecules
    • peptide therapies
  • Projects
  • Insights
    • Articles
  • News & Updates
  • Contact us
  • Languages
    • You need WPML plugin for this to work. You can remove it from Header builder.